Start of marketing in Italy after a successful pilot

STOCKHOLM, SWEDEN/ACCESSWIRE/March 22, 2022/ iZafe Group (STO:IZAFE-B)

iZafe Group (publ.) hereby announces that partner Remedio SRL is ready with its pilot from Dosell which will be included in its Sempli Farma concept. A first order of 50 Dosell will be sent to Italy this week.

“We have for a long time tested and evaluated Dosell with the Sempli Farma concept, which allows safer and easier medication at home with the local pharmacy. As part of all the parties in place, I brought in a sales team of 3 people who will actively work with sales to the 20,000 pharmacies in Italy, and will also find partners who will offer Sempli Farma, including Dosell in its portfolios”, says Alessando Iadecola, CEO of Remedio SRL

“We are very pleased with this news for several reasons. We think the concept is very exciting where you are not limited by the sachet market as the sachets are included as part of the service and we see great potential for similar concepts in other countries. And that the Italian market has enormous potential where there are more than 8.8 million people who are over 65 and take more than 5 medications a day.
With 20 billion euros in annual costs linked to incorrect medication in Italy, we hope that the Sempli Farma concept can contribute to safer care where lives are saved and injuries avoided, as well as significant savings for the society,” says Anders Segerström, CEO of iZafe Group AB.

About Sempli Farma by Remedio SRL
Italian healthcare company Remedio has built a network of strategically selected partners in Italy to find a combination of different medication management aids and delivery channels that allow older people to stay at home longer. Unlike in Sweden, the possibility of receiving medication on a dose roll did not exist in Italy; this inspired Remedio to launch the concept of sachets and develop the complete Sempli Farma solution.

Sempli Farma is a service that connects pharmacists with the patient and their relatives via a pharmacy through a closed drug distribution system. The healthcare concept aims to reduce healthcare costs and rationalize the Italian healthcare system. Dosell becomes the ultimate end component by delivering the dose packets while verifying drug compliance and obtaining statistics.

About Dosel
The Dosell medical robot is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated with wellness platforms and is sold as one of many integrated digital aids through partners.
In a Swedish report, it is estimated that 3,000 Swedes die each year from drug-related injuries and that 6-16% of hospital admissions are drug-related. The costs of preventable drug-related injuries are estimated to be between 5.6 and 24.6 billion Swedish crowns per year.
Dosell notifies the patient when it is time to take the medication, and if the medication is not taken despite reminders, Dosell alerts healthcare professionals or loved ones who can quickly prevent injury and improve compliance, minimizing drug-related injuries.
Read more on www.dosell.se

contacts

Anders Segerström, Managing Director
E-mail: [email protected]
Telephone number: +46 70-875 14 12

iZafe Group AB (ed.)
Södra Fiskartorpsvägen 20
114 33 Stockholm

E-mail: [email protected]
www.izafe.se/investor-relations/

About Us

iZafe Group is a Swedish life sciences company that develops and markets medical and digital security solutions to create safer medication handling at home. The company’s digital medication dispenser, Dosell, reduces the risk of incorrect medication, increases safety for family and loved ones and relieves pressure on public care staff. The products form a holistic concept that facilitates the medication of patients and offers those who are treated at home better conditions for a happy and safe life. Today, customers are public and private healthcare providers in Sweden, the Nordic countries and around the world. iZafe Group primarily sells through well-established partners who already have long and deep customer relationships with priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company’s certified advisor. Telephone: +46 (0) 8 528 00 399. Email: [email protected]. Further information is available at www.izafe.se/investor-relations/.

Attachments

Start of marketing in Italy after a successful pilot

THE SOURCE: iZafe Group

See the source version on accesswire.com:
https://www.accesswire.com/694101/Commercialization-Start-in-Italy-after-Successful-Pilot

Comments are closed.